Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Patrono C; Coller B; FitzGerald GA; Hirsh J; Roth GChest 2004[Sep]; 126 (3 Suppl): 234S-264SThis article discusses platelet active drugs as part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. New data on antiplatelet agents include the following: (1) the role of aspirin in primary prevention has been the subject of recommendations based on the assessment of cardiovascular risk; (2) an increasing number of reports suggest a substantial interindividual variability in the response to antiplatelet agents, and various phenomena of "resistance" to the antiplatelet effects of aspirin and clopidogrel; (3) the benefit/risk profile of currently available glycoprotein IIb/IIIa antagonists is substantially uncertain for patients with acute coronary syndromes who are not routinely scheduled for early revascularization; (4) there is an expanding role for the combination of aspirin and clopidogrel in the long-term management of high-risk patients; and (5) the cardiovascular effects of selective and nonselective cyclooxygenase-2 inhibitors have been the subject of increasing attention.|Administration, Oral[MESH]|Aspirin/*administration & dosage/adverse effects/pharmacokinetics[MESH]|Clopidogrel[MESH]|Coronary Thrombosis/blood/*drug therapy[MESH]|Evidence-Based Medicine[MESH]|Humans[MESH]|Myocardial Revascularization[MESH]|Platelet Aggregation Inhibitors/*administration & dosage/adverse effects/pharmacokinetics[MESH]|Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors[MESH]|Randomized Controlled Trials as Topic[MESH]|Risk Factors[MESH]|Thromboembolism/blood/*drug therapy[MESH]|Ticlopidine/*administration & dosage/adverse effects/*analogs & derivatives/pharmacokinetics[MESH]|Treatment Outcome[MESH] |